amyris inc
play

Amyris, Inc. INVESTOR PRESENTATION September 2020 Investor - PowerPoint PPT Presentation

Oct 24, 2023 •199 likes •438 views

Amyris, Inc. INVESTOR PRESENTATION September 2020 Investor Presentation | September 2020 FORWARD LOOKING STATEMENT This presentation and oral statements accompanying this presentation contain forward-looking statements, and any statements other

  1. Amyris, Inc. INVESTOR PRESENTATION September 2020

  2. Investor Presentation | September 2020 FORWARD LOOKING STATEMENT This presentation and oral statements accompanying this presentation contain forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as expected revenue, including revenues from consumer, ingredients, collaboration & grants, recurring revenue, EBITDA, gross profit, gross margin and operating expenses in 2020, including related growth rates, anticipated growth for Amyris’s businesses, expected debt reduction in 2020, and expectations regarding Amyris’s financial and operational results and ability to achieve its business plan in 2020 and beyond. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris’s liquidity and ability to fund operating and capital expenses, risks related to potential delays or failures in development, production or commercialization of products, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise. NON-GAAP FINANCIAL INFORMATION This presentation and oral statements accompanying this presentation contain both GAAP and non-GAAP financial information. Amyris considers non-GAAP financial information to be a helpful measure to assess its operational performance and for financial and operational decision-making. Totals in this presentation may not foot due to rounding.

  3. Investor Presentation | September 2020 About Amyris Strong growth prospects driven by consumer megatrends and underpinned by proprietary science • Leading synthetic biology portfolio of platform FY 2018-2019 Sales $180 ($ in millions) molecules driving speed to market and enabling deep +140% $160 strategic partnerships $140 $120 $100 $80 153 • ESG-driven high growth Clean Beauty consumer $60 $40 brands disrupting the beauty space 64 $20 $0 FY 2018 FY 2019 • Proprietary functional ingredients for flavors and 56% fragrance, and health and wellness end-markets 2019 GROSS MARGIN (NON-GAAP) Page 3

  4. H.C. Wainwright Investor Conference | September 14, 2020 Experienced Leadership Team and Board of Directors Leadership Team Daya Fields President, Pipette & Purecane Board of Directors Geoffrey Duyk M.D., Ph.D John Melo Partner, Circularis Partners President & CEO, Amyris Philip Eykerman Steve Mills EVP, Corp Strategy & Acquisitions, DSM Former CFO, ADM and Amyris Christoph Goppelsroeder Carole Piwnica President and CEO, DSM Nutritional products Director, Sanofi/ Director, Rothschild / Chairman, Arianna S.A. Dr. Frank Kung Lisa Qi Founding Member, Vivo Capital Director, Daling Family/GM YSL China Julie Spencer Washington James McCann Chief Marketing & Communications Officer, Trinity Health Founder and Chairman, 1-800-FLOWERS.COM Patrick Yang Ph.D. EVP, Juno Therapeutics/SVP Operations Roche/EVP Operations Genentech Page 4

  5. Investor Presentation | September 2020 Amyris’ Technology Accelerating Key Technical Metrics Molecules commercialized per year ~2-4 Industry Disruption Number of PhD’s ~85 Number of US and foreign patents 871 issued and applications pending Addressable Market Molecules Manufactured 10 Growth markets that are accelerated Pipeline of molecules in development 17 by Consumers push for Health, 9 Clean and Sustainable 48 From First Strain to First Pilot Run (2012-2019 ) • Clean Beauty to become the standard in beauty $Billion 200 • Natural flavors and fragrances is the clear direction • Alternative sweetener with great taste and mouthfeel is a winner Beauty (Skin Care + Baby) Flavors & Fragrance Alternative Sweeteners Page 5

  6. Investor Presentation | September 2020 Serving Attractive Growth Markets Sales by End Markets Sales by Category Sales by Geography 6% 24% 24% 19% 39% Consumer 2 36% Sales 1 Sales 1 Sales 1 76% 4% Ingredients 3 40% 47% 4% 28% 29% Clean Skin Care North America Consumer & Ingredients Health EU and UK Collaboration & Grants Flavors Asia Perfumes Latin America Personal and Home Care 1 Based on preliminary unaudited Q1 2020 performance 2 Biossance TM , Pipette TM , Purecane TM 3 Flavors and Fragrance, Natural Sweeteners, Personal and Home Care Page 6

  7. Investor Presentation | September 2020 Synthetic Biology Driving Growth in Sustainable and Clean Brands The #1 Supplier of Clean, Sustainable ingredients World’s leading synthetic biology platform to Leading Brands The world’s leading synthetic biology platform. Nine commercialized products delivering the most profitable and fastest growing revenue in synthetic biology High growth Clean Beauty consumer brands Our Biossance & Pipette Clean Skin Care brands are the fastest growing in North America – 2019 Revenue of $17m growing >300% YOY Proprietary functional ingredients Our ingredients are inside over $10B of consumer purchases sold through 3,000+ of the world’s leading brands – 2019 Revenue of $48M growing >80% YOY Owner of the Leading Clean Health and Beauty Clean and safe ingredients are more important than ever before Brands in North America Our growth is accelerating through COVID-19. Consumers are transitioning to clean and safe ingredients faster than ever and we are a leading supplier with advantaged technology Page 7

  8. Investor Presentation | September 2020 Fast Time-to-Market Product Design With End Solution in Mind We have defined the Gold Standard for Clean Chemistry Industrialized Synthetic Biology delivery in 12 months • Product application design at industrial scale delivered in <12 months • Full cycle clean fermentation produces sustainable molecules at scale • Fast time to market at low cost. One new yeast strain every 2.5 minutes • Robotics, automation and machine learning are powering genetic coding. Iteration cycles measured in minutes rather than weeks Dedicated pipeline: Automated Scientist and state-of-the-art robotics Page 8

  9. Investor Presentation | September 2020 Platform Molecules Connected Through Market Leaders On track for third consecutive year of doubling recurring revenue** Owned Brands set the Standard #1 Producer of Clean Ingredients We Partner with Market Leaders for Consumers EXISTING • Amazon • L’Oreal • Farnesene • Amore Pacific • Nikko • Patchouli • ASR • Squalane • DSM The #1 The #1 • Sclareol Supplier of Supplier of • buybuy BABY • Sanofi • Manool Natural and Natural and • DARPA • Sephora • Bisabolol Sustainably Sustainably • DOE • Fragrance 5* • Takasago sourced sourced • Flavor 1* Platform Platform • Estee Lauder • Target • Reb M Molecules Molecules • Firmenich • Walmart • Gates Foundation • Yifan PIPELINE • HMO • Givaudan • Shisheido • Vitamins • Cannabinoids *Confidential products **Recurring revenue includes all revenue that has a multiyear contract and revenue from our consumer brands Page 9

  10. Investor Presentation | September 2020 Our Strategic Priorities Driving a multi-faceted agenda to deliver value for consumers, partners and shareholders 1 High growth consumer • Build on our Clean Beauty market leadership and double sales YOY brands • Extend offering of clean and safe ingredients and product 2 Scientific and commercial • Execute on R&D collaboration programs to scale 3-4 new molecules yearly collaboration • Establish market leadership in sustainable Health and Wellness markets 3 • Deliver lower unit costs targeting gross margins >60% of sales Supply chain optimization • Drive agile and robust supply network to support sales growth Improved balance sheet, • Reduced balance sheet leverage. Be fully funded to deliver growth 4 • Deliver on path to sustained cash generation from operational earnings and cash flow performance Page 10

  11. Investor Presentation | September 2020 2020 BIOSSANCE IS LEADING THE WAY Return on Advertising Spend: Q3 2019: $3.76 Q4 2019: $5.43 Q1 2020: $9.20 Page 11

  12. Investor Presentation | September 2020 Biossance Brand: DNA Pillars FOUNDER SOURCE IDENTITY PERSONALITY PRODUCT We originate from… We source from… We are… We act… We make… BERKELEY BRAZILIAN APPROACHABLE SELFLESS CLEAN-ICAL BIOTECHNOLOGY SUGARCANE SCIENCE EDUCATION (Equally clinical & clean) Page 12

  13. Investor Presentation | September 2020 SQUALANE Biossance Brand Key Initiatives NATURE’S BEST MOISTURIZER 1 Clean Academy Leader in Clean Beauty education 2 City Takeover 360 Takeovers, including NYC and LA 3 Become the most loyal brand With the most passionate followers 4 BIOSSANCE SAVES OVER Digital Leadership Best in class experience, engagement and 2M SHARKS A YEAR platforms Page 13

More recommend